{"filings":[{"id":95972,"accession_number":"0001193125-26-205305","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.01","3.01","5.01","5.03","3.03","5.02","8.01","9.01"],"status":"ready","headline":"Terns Pharmaceuticals acquired by Merck for $53/share; shares to be delisted","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Offer expired May 4, 2026 with 100,091,794 shares (86.36%) validly tendered; minimum condition met.","On May 5, Purchaser accepted tendered shares and promptly merged Terns into a wholly owned Merck subsidiary.","Each share converted into $53 cash; outstanding in-the-money options and RSUs cashed out per agreement.","All incumbent directors and officers ceased; replaced by Merck designees. Charter and bylaws amended.","Nasdaq delisting effective May 5; Form 15 to be filed to terminate SEC registration and reporting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95971,"accession_number":"0001193125-26-179062","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA grants Breakthrough Therapy Designation to TERN-701; Merck acquisition mentioned in press release","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Breakthrough Therapy Designation for TERN-701 in Ph+ CML-CP patients without T315I mutation, previously treated with 2+ TKIs.","Designation based on CARDINAL Phase 1/2 data: encouraging major molecular response and deep molecular response rates at week 24.","TERN-701 safety profile: majority of adverse events low grade; low severe adverse events and discontinuations.","Press release also notes recent agreement for Merck to acquire Terns (Nasdaq: TERN).","CEO Amy Burroughs cites BTD and Merck deal as potential acceleration to pivotal trial and patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109444,"accession_number":"0001193125-26-122785","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Merck to acquire Terns for $53.00/share ($6.7B equity value); adds CML candidate TERN-701","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merck subsidiary will pay $53.00 per share in cash, representing ~$6.7B equity value; ~$5.7B net of acquired cash.","Premium of 31% to 60-day and 42% to 90-day VWAP as of March 24, 2026.","Terns’ lead candidate TERN-701 is an investigational allosteric BCR::ABL1 inhibitor in Phase 1/2 for CML; FDA Orphan Drug Designation granted March 2024.","Transaction subject to HSR waiting period, tender of >50% of Terns shares, and other customary conditions; expected to close Q2 2026.","Merck expects ~$5.8B charge (~$2.35/share) in Q2 and full year 2026 GAAP and non-GAAP results related to the acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109443,"accession_number":"0001193125-26-019426","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Terns Pharma secures exclusive worldwide license for TERN-701 from Hansoh; $1M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment grants Terns exclusive, perpetual, worldwide (excl. Hansoh territory) license to Hansoh patents for TERN-701.","Terns pays $1.0M upfront fee plus tiered royalties of 0.75%-1.25% on net sales covered by licensed patents.","License covers TERN-701 as sole active ingredient; replaces prior non-exclusive, non-sublicensable license.","Hansoh territory remains mainland China, Taiwan, Hong Kong, and Macau."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109442,"accession_number":"0001193125-26-008907","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Terns announces $1.0B cash runway; TERN-701 pivotal trial planned late 2026/early 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Year-end 2025 unaudited cash ~$1.0B, expected to fund operations into 2031 including potential TERN-701 launch.","Completed December 2025 public offering of 18.7M shares, gross proceeds ~$747.5M.","TERN-701 granted FDA Fast Track for CML; CARDINAL trial enrolled 85+ patients as of Dec 8, 2025.","2026 milestones: pivotal dose selection and EOP2 FDA interaction mid-2026; updated CARDINAL data by 2H26; start 2L+ pivotal trial late 2026/early 2027.","New CARDINAL cohort to evaluate TERN-701 500mg QD in patients with BCR-ABL mutations including T315I."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125934,"accession_number":"0001193125-25-315065","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Terns Pharmaceuticals prices upsized $650M public offering of 16.25M shares at $40/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 16.25M shares at $40/share upsized; underwriters' option for 2.44M shares exercised in full.","Estimated net proceeds ~$705.8M to fund TERN-701 trials, manufacturing, and potential commercial launch prep.","Cash runway extended into 2031, based on existing cash plus estimated offering net proceeds.","Jefferies, TD Cowen, Leerink Partners lead underwriters; closing expected Dec 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125933,"accession_number":"0001193125-25-311202","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Terns reports 64% MMR rate in Phase 1 CARDINAL trial of TERN-701 in CML; selects 320/500 mg RP2D","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Overall MMR rate of 64% (18/28) achieved by 24 weeks; cumulative MMR rate 74% (28/38).","At doses >=320 mg QD (RP2D), MMR achievement 75% (18/24) by 24 weeks; DMR rate 36% (10/28).","Safety: 87% patients on treatment; no DLTs; low Grade 3+ cytopenia (<10%); common TEAEs diarrhea, headache, nausea.","Enrollment surpassed 85 patients; company plans pivotal Phase 3 trials in 2L+ and 1L CML in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125932,"accession_number":"0001193125-25-274282","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Terns reports Q3 net loss $24.6M; TERN-701 CML data 75% MMR at 24 weeks; halts TERN-601 GLP-1 obesity program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["TERN-701 Phase 1 CARDINAL trial: overall MMR rate 75% by 24 weeks; 69% in patients with lack of efficacy to prior TKI.","TERN-601 Phase 2 obesity study: 4.6% placebo-adjusted weight loss, 12% discontinuation due to AEs, reversible liver enzyme elevations; development stopped.","Cash, cash equivalents and marketable securities of $295.6M as of Sep 30, 2025, expected to fund operations into 2028.","Q3 2025 net loss $24.6M vs $21.9M in Q3 2024; R&D expense rose to $19.9M from $15.2M.","Seeking strategic partners for TERN-501 (THR-β agonist) and TERN-801 (GIPR antagonist) metabolic programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125931,"accession_number":"0001193125-25-261798","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"TERN-701 Phase 1 CARDINAL trial shows 75% cumulative MMR rate by 24 weeks in refractory CML; abstract at ASH","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["75% (24/32) overall cumulative MMR rate by 24 weeks; 64% (14/22) achieved MMR, 100% (10/10) maintained MMR, no MMR loss.","In difficult subgroups: 69% MMR in patients with lack of efficacy to last TKI, 60% with prior asciminib, 67% with prior asciminib/ponatinib/investigational TKI.","Safety: 87% (48/55) remain on treatment; no DLTs; Grade 3+ TEAEs <10% (neutropenia 7%, thrombocytopenia 4%).","Patients heavily pretreated: median 3 prior TKIs, 64% discontinued last TKI due to lack of efficacy, 36% had prior asciminib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125930,"accession_number":"0001193125-25-245404","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Terns Pharma discontinues obesity drug TERN-601 after Phase 2 miss; liver enzyme signals seen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Max placebo-adjusted weight loss 4.6% (p<0.0001) at 500 mg dose; 11.9% discontinued due to AEs.","Grade 3 liver enzyme elevations in 3 participants post-treatment, 2 deemed drug-related.","Company will not advance TERN-601 or further invest in metabolic assets.","Reiterates focus on TERN-701 for CML with clinical data expected this quarter.","GI AEs most common: nausea 56%, vomiting 26.9%; all mild/moderate and dose-related."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142682,"accession_number":"0000950170-25-103071","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Terns Q2 net loss $24.1M; TERN-701 CML data and TERN-601 obesity data expected by year-end 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.1M for Q2 2025 vs $22.7M in Q2 2024; R&D expenses $20.4M.","Cash, equivalents and securities $315.4M as of June 30, 2025; runway into 2028.","Phase 1 CARDINAL trial of TERN-701 in CML: efficacy/safety with 6-month MMR rates expected in 4Q25.","Phase 2 FALCON trial of TERN-601 in obesity completed enrollment; 12-week top-line data expected early 4Q25.","Company focusing on advancing TERN-701 in oncology; seeking partners for metabolic assets (TERN-800, TERN-501)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160743,"accession_number":"0000950170-25-086758","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Terns Pharmaceuticals elects three directors and ratifies EY as auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Robert Azelby elected with 56.4M votes for, 3.2M withheld.","Hongbo Lu elected with 52.0M votes for, 7.6M withheld.","Heather Turner elected with 58.3M votes for, 1.3M withheld.","Ratification of Ernst & Young as independent auditor for FY2025 passed with 64.8M for, 28.5K against.","No broker non-votes on ratification; two proposals considered at June 11, 2025 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160742,"accession_number":"0000950170-25-066952","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Terns Q1 net loss $23.9M; advances TERN-701 CML and TERN-601 obesity trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.9M ($0.26 EPS) vs $22.4M a year ago; R&D flat at $18.7M, G&A up to $8.7M.","Cash, equivalents and marketable securities $334.3M at March 31, 2025; runway into 2028.","Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 (CML); 6-month MMR data expected Q4 2025.","Phase 2 FALCON trial of TERN-601 (obesity) enrolling; top-line 12-week weight loss data due Q4 2025."],"consensus_eps_estimate":-0.2856,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178946,"accession_number":"0000950170-25-042663","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Terns Pharma reports FY2024 net loss of $88.9M; cash runway into 2028; clinical milestones for CML and obesity","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 net loss $88.9M ($1.12/share), vs $90.2M in FY2023; R&D expenses $70.1M, G&A $31.8M.","Cash, cash equivalents and marketable securities $358.2M as of Dec 31, 2024, up from $263.4M; expected runway into 2028.","TERN-701 Phase 1 CARDINAL dose expansion to start 2Q25, with additional safety/efficacy data in 4Q25.","TERN-601 Phase 2 FALCON enrolled first patient in March 2025; 12-week top-line data expected 4Q25.","Appointed Andrew Gengos as CFO and Robert Azelby to board in February 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178945,"accession_number":"0000950170-25-025635","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Terns Pharma appoints Andrew Gengos as CFO effective Feb 24, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Gengos named CFO effective Feb 24; salary $510K, bonus target 40%, option for 750K shares vesting over 4 years.","Most recently CFO/Chief Business Officer at Athira Pharma (May 2023-Oct 2024); previously CEO at ImmunoCellular and Neuraltus.","CEO Amy Burroughs remains CEO but steps down as principal financial officer; David Strauss remains VP Finance and steps down as principal accounting officer.","Stock option exercise price equals closing price on start date; 25% vests at one year, then monthly over three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178944,"accession_number":"0000950170-25-024187","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Terns Pharmaceuticals appoints Robert Azelby to board; Carl Gordon resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Azelby appointed to Board as Class I director effective Feb 20, 2025, and joins Compensation Committee.","Carl Gordon resigned from Board effective Feb 20, 2025 after over seven years; departure not due to disagreement.","Azelby brings 25+ years biopharma experience including CEO roles at Eliem Therapeutics and Alder BioPharmaceuticals.","Azelby received option to purchase 90,000 shares vesting over three years under non-employee director compensation plan.","Company highlights TERN-701 for chronic myeloid leukemia and obesity programs approaching clinical readouts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178943,"accession_number":"0000950170-25-015501","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Terns Pharmaceuticals CFO Mark Vignola Departs; CEO Burroughs Takes Interim CFO Role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Mark Vignola separated effective Feb 1, 2025; entered consulting agreement through July 2025.","CEO Amy Burroughs assumes principal financial officer; VP Finance David Strauss named principal accounting officer, each on interim basis.","Vignola receives $30k/month for first two months, $15k/month for next two, then hourly; equity awards continue vesting.","Departure not due to any disagreement with company operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195631,"accession_number":"0000950170-24-132452","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Terns reports positive Phase 1 CARDINAL data for TERN-701 in CML; MMR rate 50% at 3 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["15 patients enrolled across 160mg, 320mg, 400mg QD; 14 of 15 remain on treatment as of Oct 28, 2024 cutoff.","Cumulative MMR rate 50% (5/10) in non-T315i patients with ≥3 months treatment or MMR at baseline.","No dose-limiting toxicities, AE-related discontinuations, dose reductions, or Grade 3+ treatment-related AEs.","At 160mg and 320mg, free drug concentrations 4- and 8-fold above efficacious in vivo exposures.","Dose expansion to start 1H25; longer-term MMR data expected in 4Q25."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195630,"accession_number":"0000950170-24-127964","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Terns Pharmaceuticals appoints Heather Turner to board; Ann Taylor resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Heather Turner, former CEO of Carmot Therapeutics, appointed to Board of Directors effective Nov 18.","Ann Taylor resigned effective Nov 18; departure not due to any disagreement with company operations.","Turner brings 25 years biotech experience; led Carmot's $3.1B acquisition by Roche.","Turner also appointed to Audit Committee; eligible for standard non-employee director compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195629,"accession_number":"0000950170-24-125435","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Terns Pharma Q3 net loss $21.9M; cash $372.8M; TERN-701 data Dec 2024, TERN-601 Phase 2 start 2Q25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.9M ($0.28/share) vs $29.8M loss ($0.42) in Q3 2023; R&D $15.2M, G&A $9.8M.","Cash, equivalents and marketable securities $372.8M (incl. $172.7M equity raise in Sep) providing runway into 2028.","Interim Phase 1 CARDINAL data for TERN-701 (allosteric BCR-ABL TKI in CML) expected early December 2024.","Phase 2 trial for TERN-601 (oral GLP-1R agonist for obesity) to start early 2Q25; initial 12-week data in 2H25."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211890,"accession_number":"0001193125-24-217444","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Terns Pharmaceuticals prices upsized $150M public offering; net proceeds ~$162M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 11.9M common shares at $10.50 and 2.38M pre-funded warrants at $10.50 per underlying share.","Underwriters' option for 2.145M additional shares exercised in full; total gross proceeds ~$150M before discounts.","Estimated net proceeds of $161.9M including option; cash runway extended into 2028.","Proceeds to fund clinical trials, development of TERN-701, TERN-601 and TERN-800 series, and working capital.","Jefferies and TD Cowen lead book-running managers; closing expected September 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211889,"accession_number":"0000950170-24-104550","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Terns Pharma reports positive Phase 1 data for oral GLP-1R agonist TERN-601; max placebo-adjusted weight loss 4.9%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TERN-601 achieved 4.9% placebo-adjusted mean weight loss at 740 mg QD over 28 days (p<0.0001); 5.5% absolute mean loss.","67% of top-dose participants lost ≥5% baseline body weight; no treatment-related dose interruptions or discontinuations.","Over 95% of AEs were mild; all GI events mild-to-moderate; no serious AEs or clinically meaningful lab/vital changes.","Company plans to initiate Phase 2 in 2025, with optimal dose range identified and no additional dose exploration needed.","Terns highlights distinct drug properties (low solubility, high gut permeability, low free fraction) as potential advantages over other oral GLP-1R agonists."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211888,"accession_number":"0000950170-24-090761","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Terns Q2 net loss $22.7M; cash $225M; TERN-601 Ph1 data Sep, TERN-701 data Dec 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.7M for Q2 2024 ($0.31/share) vs $17.9M ($0.25/share) in Q2 2023.","Cash, equivalents and marketable securities $225.3M, expected to fund operations into 2026.","Top-line Phase 1 data for oral GLP-1 TERN-601 (obesity) expected September 2024.","Interim Phase 1 CARDINAL trial data for allosteric BCR-ABL TERN-701 (CML) expected December 2024.","Appointed Elona Kogan as CLO; CFO search underway; Mark Vignola to serve through Jan 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211887,"accession_number":"0000950170-24-087284","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Terns appoints new Chief Legal Officer; CFO and General Counsel to depart in planned transitions","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elona Kogan appointed Chief Legal Officer effective July 29; previously CLO at Seer, Inc.","CFO Mark Vignola to leave by Feb 1, 2025 or upon successor; receives $475k severance plus $500k retention bonus.","General Counsel Bryan Yoon steps down, becomes COO/Special Counsel until Sep 3, 2024; receives $490,700 severance.","Search for new CFO underway; Vignola and Yoon remain in transition roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211886,"accession_number":"0000950170-24-081531","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Terns Pharmaceuticals extends office lease for 36 months through October 2027","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Lease extended from Nov 1, 2024 to Oct 31, 2027 for 9,751 sq ft in Foster City, CA.","Monthly base rent: $0 (Nov '24-Jan '25), then $43,879.50 rising to $46,551.76 by 2026-27.","Tenant pays $43,789.50 as prepaid rent for Feb 2025 upon execution of amendment.","Option to extend for additional three years with 9-12 months written notice; first refusal right deleted.","Landlord may convert building to life science lab; tenant gets rent abatement and termination rights for significant disruption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230680,"accession_number":"0000950170-24-072462","cik":1831363,"company_name":"Terns Pharmaceuticals, Inc.","ticker":"TERN","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Terns Pharmaceuticals shareholders elect Kindler and Burroughs as directors; ratify Ernst & Young as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jeffrey Kindler elected with 45,958,352 votes for, 6,735,358 withheld, 5,131,121 broker non-votes.","Amy Burroughs elected with 52,570,019 votes for, 123,691 withheld, 5,131,121 broker non-votes.","Ernst & Young ratified as independent auditor for FY2024 with 57,570,954 for, 23,950 against, 229,927 abstentions.","Annual Meeting held June 10, 2024; 64,674,780 shares outstanding and entitled to vote as of record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":6116850000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}